Indication

Angiotensinogen

1 clinical trial

1 product

Clinical trial

A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1

Status: Completed, Estimated PCD: 2023-02-07

Product